Complete Filing Data
Alto Neuroscience, Inc. reported Temporary Equity Shares Outstanding of 0 shares for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Alto Neuroscience, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$63.2M | -$61.4M | -$36.3M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $123.0K | -$22.0K | -$33.0K |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$30.0K | -$22.0K | -$33.0K |
| Research And Development Expense | $45.6M | $47.0M | $30.3M |
| Other Comprehensive Income Loss Net Of Tax | -$63.1M | -$61.5M | -$36.3M |
| Operating Income Loss | -$66.4M | -$68.6M | -$37.8M |
| Operating Expenses | $66.4M | $68.6M | $37.8M |
| Nonoperating Income Expense | $3.1M | $7.2M | $1.5M |
| Interest Expense Nonoperating | $2.5M | $1.4M | $1.4M |
| General And Administrative Expense | $20.7M | $21.6M | $7.5M |
| Interest Expense Noncash | $729.0K | $393.0K | $396.0K |
| Research And Development Expense Noncash | $0.00 | $735.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$14.2M | -$17.7M | -$15.2M | -$16.8M | -$16.0M | -$13.4M | -$9.1M | -$8.7M | -$7.3M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -$17.0K | $17.0K | $115.0K | -$6.0K | -$5.0K | -$5.0K | -$10.0K | -$11.0K | -$19.0K |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$5.0K | -$5.0K | -$19.0K | -$6.0K | -$5.0K | -$5.0K | -$10.0K | -$11.0K | -$19.0K |
| Research And Development Expense | $10.5M | $13.1M | $10.0M | $13.1M | $13.2M | $10.0M | $8.0M | $7.1M | $5.6M |
| Other Comprehensive Income Loss Net Of Tax | -$14.2M | -$17.7M | -$15.1M | -$16.8M | -$16.0M | -$13.4M | -$9.2M | -$8.7M | -$7.3M |
| Operating Income Loss | -$15.0M | -$18.7M | -$15.7M | -$18.9M | -$18.3M | -$14.4M | -$9.7M | -$9.1M | -$7.2M |
| Operating Expenses | $15.0M | $18.7M | $15.7M | $18.9M | $18.3M | $14.4M | $9.7M | $9.1M | $7.2M |
| Nonoperating Income Expense | $770.0K | $976.0K | $507.0K | $2.1M | $2.3M | $969.0K | $577.0K | $462.0K | -$83.0K |
| Interest Expense Nonoperating | $650.0K | $646.0K | $598.0K | $349.0K | $347.0K | $346.0K | $363.0K | $327.0K | $324.0K |
| General And Administrative Expense | $4.4M | $5.6M | $5.7M | $5.8M | $5.2M | $4.4M | $1.8M | $2.1M | $1.6M |
| Interest Expense Noncash | $180.0K | $98.0K | $102.0K | ||||||
| Research And Development Expense Noncash |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $0.00 | $141.5M | $72.2M |
| Stockholders Equity | $151.1M | $151.5M | -$71.7M | -$38.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $177.0M | $168.7M | $82.5M | $48.3M |
| Temporary Equity Shares Conversion Of Convertible Securities | 29.9M | |||
| Retained Earnings Accumulated Deficit | -$201.6M | -$138.4M | -$77.0M | |
| Property Plant And Equipment Net | $1.9M | $2.7M | $1.1M | |
| Prepaid Expense And Other Assets Current | $1.2M | $1.1M | $2.8M | |
| Preferred Warrant Liability Conversion To Equity | $0.00 | $1.6M | $0.00 | |
| Other Assets | $338.0K | $4.0K | $131.0K | |
| Operating Lease Right Of Use Asset Amortization Expense | $774.0K | $337.0K | $280.0K | |
| Long Term Debt Noncurrent | $16.2M | $10.3M | $9.9M | |
| Liabilities Current | $11.3M | $10.0M | $5.6M | |
| Liabilities And Stockholders Equity | $184.7M | $177.5M | $86.6M | |
| Liabilities | $33.5M | $26.1M | $16.8M | |
| Deferred Stock Issuance Costs Reclassification To Equity | $0.00 | $1.4M | $0.00 | |
| Common Stock Value Outstanding | $3.0K | $3.0K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $8.3M | $86.2M | $34.2M | |
| Cash And Cash Equivalents At Carrying Value | $176.5M | $168.2M | $82.5M | |
| Assets Current | $177.7M | $169.3M | $85.4M | |
| Assets | $184.7M | $177.5M | $86.6M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $22.0K | -$101.0K | -$79.0K | |
| Accrued Liabilities Current | $8.9M | $8.4M | $4.5M | |
| Accounts Payable Current | $1.9M | $1.6M | $1.1M | |
| Operating Lease Right Of Use Asset | $4.3M | $5.0M | $0.00 | |
| Restricted Cash Noncurrent | $500.0K | $500.0K | $0.00 | |
| Gain Loss On Sale Of Property Plant Equipment | -$156.0K | -$52.0K | -$140.0K | |
| Operating Lease Liability Noncurrent | $3.8M | $4.5M | $0.00 | |
| Gains Losses On Extinguishment Of Debt | -$681.0K | $0.00 | ||
| Convertible Debt | $2.2M | $1.3M | $0.00 | |
| Temporary Equity Value Conversion Of Convertible Securities | $141.5M | |||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $0.00 | $5.2M | $0.00 | |
| Repayments Of Long Term Debt | $10.2M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $97.1M | $97.1M | $97.1M |
| Stockholders Equity | $111.6M | $123.4M | $139.1M | $165.1M | $179.8M | $193.1M | -$61.1M | -$52.6M | -$45.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $138.3M | $148.1M | $161.3M | $182.2M | $193.6M | $205.9M | $51.3M | $59.0M | $65.8M |
| Temporary Equity Shares Conversion Of Convertible Securities | 29.9M | ||||||||
| Retained Earnings Accumulated Deficit | -$185.5M | -$171.3M | -$153.6M | -$123.2M | -$106.4M | -$90.4M | |||
| Property Plant And Equipment Net | $2.0M | $2.3M | $2.5M | $2.4M | $1.4M | $1.6M | |||
| Prepaid Expense And Other Assets Current | $1.6M | $2.3M | $2.8M | $1.8M | $2.3M | $2.4M | |||
| Preferred Warrant Liability Conversion To Equity | $0.00 | $1.6M | $0.00 | ||||||
| Other Assets | $570.0K | $570.0K | $569.0K | $4.0K | $4.0K | $58.0K | |||
| Operating Lease Right Of Use Asset Amortization Expense | $190.0K | $72.0K | $75.0K | ||||||
| Long Term Debt Noncurrent | $20.3M | $20.1M | $19.9M | $6.6M | $7.7M | $8.8M | |||
| Liabilities Current | $9.0M | $8.1M | $7.3M | $14.0M | $9.8M | $8.0M | |||
| Liabilities And Stockholders Equity | $147.0M | $157.9M | $171.9M | $191.6M | $197.4M | $209.9M | |||
| Liabilities | $35.4M | $34.5M | $32.8M | $26.6M | $17.6M | $16.8M | |||
| Deferred Stock Issuance Costs Reclassification To Equity | $0.00 | $1.4M | $0.00 | ||||||
| Common Stock Value Outstanding | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$7.5M | $123.3M | $17.4M | ||||||
| Cash And Cash Equivalents At Carrying Value | $137.8M | $147.6M | $160.8M | $181.7M | $193.1M | $205.9M | |||
| Assets Current | $139.4M | $149.8M | $163.5M | $183.5M | $195.4M | $208.3M | |||
| Assets | $147.0M | $157.9M | $171.9M | $191.6M | $197.4M | $209.9M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $14.0K | $31.0K | $14.0K | -$95.0K | -$89.0K | -$84.0K | |||
| Accrued Liabilities Current | $7.0M | $6.5M | $5.9M | $8.2M | $5.7M | $4.4M | |||
| Accounts Payable Current | $2.1M | $1.7M | $1.4M | $2.3M | $1.8M | $2.4M | |||
| Operating Lease Right Of Use Asset | $4.5M | $4.7M | $4.8M | ||||||
| Restricted Cash Noncurrent | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | ||||
| Gain Loss On Sale Of Property Plant Equipment | -$41.0K | $0.00 | |||||||
| Operating Lease Liability Noncurrent | $4.0M | $4.2M | $4.4M | $4.6M | |||||
| Gains Losses On Extinguishment Of Debt | $0.00 | $0.00 | -$681.0K | $0.00 | $0.00 | $0.00 | |||
| Convertible Debt | $2.1M | $2.0M | $1.2M | $1.3M | |||||
| Temporary Equity Value Conversion Of Convertible Securities | $141.5M | ||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||||||
| Repayments Of Long Term Debt | $10.2M | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Depreciation Depletion And Amortization | $502.0K | $373.0K | |
| Share Based Compensation | $8.1M | $7.6M | $2.9M |
| Proceeds From Stock Options Exercised | $703.0K | $187.0K | $181.0K |
| Proceeds From Issuance Initial Public Offering | $0.00 | $137.6M | $0.00 |
| Payments To Acquire Property Plant And Equipment | $24.0K | $2.1M | $470.0K |
| Net Cash Provided By Used In Operating Activities | -$51.8M | -$47.4M | -$33.4M |
| Net Cash Provided By Used In Investing Activities | -$24.0K | -$2.1M | -$470.0K |
| Net Cash Provided By Used In Financing Activities | $60.1M | $135.7M | $68.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$101.0K | $463.0K | -$291.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$289.0K | $4.0M | -$357.0K |
| Increase Decrease In Accounts Payable | $221.0K | $516.0K | -$632.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$30.0K | -$11.0K | -$8.0K |
| Proceeds From Convertible Debt | $750.0K | $1.3M | $0.00 |
| Proceeds From Issuance Of Convertible Preferred Stock | $0.00 | $70.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|
| Depreciation Depletion And Amortization | $100.0K | $171.0K | $200.0K | $100.0K | $97.0K | $100.0K | $100.0K | $86.0K |
| Share Based Compensation | $2.0M | $2.2M | $484.0K | |||||
| Proceeds From Stock Options Exercised | $198.0K | $10.0K | $0.00 | |||||
| Proceeds From Issuance Initial Public Offering | $0.00 | $137.6M | $0.00 | |||||
| Payments To Acquire Property Plant And Equipment | $24.0K | $224.0K | $21.0K | |||||
| Net Cash Provided By Used In Operating Activities | -$16.6M | -$11.0M | -$7.5M | |||||
| Net Cash Provided By Used In Investing Activities | -$24.0K | -$224.0K | -$21.0K | |||||
| Net Cash Provided By Used In Financing Activities | $9.1M | $134.6M | $25.0M | |||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.7M | $1.8M | $464.0K | |||||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$2.7M | $406.0K | $174.0K | |||||
| Increase Decrease In Accounts Payable | -$266.0K | $1.1M | -$649.0K | |||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$22.0K | -$5.0K | -$19.0K | |||||
| Proceeds From Convertible Debt | ||||||||
| Proceeds From Issuance Of Convertible Preferred Stock | $0.00 | $25.0M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 29.9M | 16.2M |
| Weighted Average Number Of Shares Outstanding Basic | 28.9M | 24.6M | 3.7M | |
| Weighted Average Number Of Diluted Shares Outstanding | 28.9M | 24.6M | 3.7M | |
| Earnings Per Share Diluted | $-2.19 | $-2.50 | $-9.73 | |
| Earnings Per Share Basic | $-2.19 | $-2.50 | $-9.73 | |
| Common Stock Shares Authorized | 500.0M | 500.0M | 52.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 31.9M | 27.0M | 3.8M | |
| Common Stock Shares Issued | 31.9M | 27.0M | 3.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.4M | 20.4M | 20.4M | |
| Weighted Average Number Of Shares Outstanding Basic | 27.1M | 27.1M | 27.0M | 27.0M | 26.9M | 17.6M | 3.7M | 3.7M | 3.7M | |
| Weighted Average Number Of Diluted Shares Outstanding | 27.1M | 27.1M | 27.0M | 27.0M | 26.9M | 17.6M | 3.7M | 3.7M | 3.7M | |
| Earnings Per Share Diluted | $-0.52 | $-0.65 | $-0.56 | $-0.62 | $-0.60 | $-0.76 | $-2.44 | $-2.33 | $-1.97 | |
| Earnings Per Share Basic | $-0.52 | $-0.65 | $-0.56 | $-0.62 | $-0.60 | $-0.76 | $-2.44 | $-2.33 | $-1.97 | |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 27.2M | 27.1M | 27.1M | 27.0M | 27.0M | 26.9M | ||||
| Common Stock Shares Issued | 27.2M | 27.1M | 27.1M | 27.0M | 27.0M | 26.9M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $8.1M | $7.6M | $2.9M |
| Investment Income Interest | $6.6M | $8.9M | $2.3M |
| Fair Value Adjustment Of Warrants | $327.0K | $297.0K | -$525.0K |
| Stock Issued During Period Value Stock Options Exercised | $707.0K | $187.0K | $181.0K |
| Interest Paid Net | $1.7M | $999.0K | $912.0K |
| Conversion Of Stock Amount Converted1 | $0.00 | $141.5M | $0.00 |
| Additional Paid In Capital | $352.8M | $290.0M | $5.4M |
| Oci Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Adjustments And Tax Parent | $153.0K | $0.00 | |
| Capital Expenditures Incurred But Not Yet Paid | $3.7M | $0.00 | |
| Adjustments To Additional Paid In Capital Warrant Issued | $524.0K | $0.00 | |
| Warrants And Rights Outstanding | $0.00 | $1.4M | |
| Stock Issued During Period Value New Issues | $133.0M | ||
| Stock Issued During Period Value Conversion Of Convertible Securities | $141.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.2M | $2.0M | $2.0M | $2.0M | $1.9M | $2.2M | $541.0K | $1.3M | $484.0K |
| Investment Income Interest | $1.5M | $1.7M | $1.8M | $2.5M | $2.7M | $1.6M | $714.0K | $667.0K | $230.0K |
| Fair Value Adjustment Of Warrants | $112.0K | $61.0K | $41.0K | $48.0K | $0.00 | $243.0K | -$226.0K | -$122.0K | -$11.0K |
| Stock Issued During Period Value Stock Options Exercised | $154.0K | $198.0K | $67.0K | $61.0K | $10.0K | $109.0K | $43.0K | ||
| Interest Paid Net | $311.0K | $248.0K | $183.0K | ||||||
| Conversion Of Stock Amount Converted1 | $0.00 | $141.5M | $0.00 | ||||||
| Additional Paid In Capital | $297.0M | $294.6M | $292.6M | $288.3M | $286.3M | $283.6M | |||
| Oci Market Risk Benefit Instrument Specific Credit Risk Gain Loss After Adjustments And Tax Parent | -$12.0K | $22.0K | $134.0K | $0.00 | $0.00 | $0.00 | |||
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $321.0K | $0.00 | ||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $524.0K | $0.00 | |||||||
| Warrants And Rights Outstanding | $0.00 | $0.00 | $0.00 | ||||||
| Stock Issued During Period Value New Issues | $132.9M | ||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $141.5M |
Most recent annual filing with the SEC: March 16, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.